News
REGN
896.82
+0.32%
2.83
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
NASDAQ · 1d ago
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
Benzinga · 1d ago
Regeneron Pharma Is Maintained at Buy by UBS
Dow Jones · 2d ago
Regeneron Pharma Price Target Raised to $1099.00/Share From $1090.00 by UBS
Dow Jones · 2d ago
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Amgen provides update on results of the Phase 2a trial for Tezspire in chronic obstructive pulmonary disease. Tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17%. The reduction was not statistically significant.
Benzinga · 2d ago
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
NASDAQ · 2d ago
REGENERON PHARMACEUTICALS INC <REGN.O>: UBS RAISES TARGET PRICE TO $1099 FROM $1090
Reuters · 2d ago
Regeneron Pharma Price Target Maintained With a $925.00/Share by Cantor Fitzgerald
Dow Jones · 2d ago
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $925 Price Target
Benzinga · 2d ago
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
Barchart · 2d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 2d ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
NASDAQ · 2d ago
Cantor Fitzgerald Reaffirms Their Hold Rating on Regeneron (REGN)
TipRanks · 3d ago
U.S. RESEARCH ROUNDUP-3M, J&J, Nuvalent
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. 3M, J&J and Nuvalent are among the companies. Analysts also raise their targets on Amazon, Tractor Supply, UnitedHealth Group and Amgen. NEW: 3M cuts its target price to $110 from $118; 10X Genomics cuts target price.
Reuters · 3d ago
Why Regeneron (REGN) Could Beat Earnings Estimates Again
NASDAQ · 3d ago
Regeneron to “vigorously defend” against DOJ on Eylea pricing complaint
Healthcare Regeneron to “vigorously defend” against DOJ on Eylea pricing complaint. The U.S. Department of Justice filed a lawsuit on allegations of misreporting the prices related to Medicare reimbursement for its blockbuster therapy. The complaint alleged that Regeneron inflated Medicare's reimbursement rates for EyleA.
Seeking Alpha · 3d ago
UPDATE 1-Regeneron to defend against DOJ complaint on drug-price manipulation
Regeneron to defend against U.S. Department of Justice complaint on drug-price manipulation. DOJ alleged the company misreported the average sales price of its macular degeneration drug Eylea. Company says it considers the complaint to be "meritless"
Reuters · 4d ago
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation. Justice Department accused company of inflating average sales price for its Eylea drug. Company says it plans to defend the case in court. The company says the complaint is "meritless"
Reuters · 4d ago
REGENERON - BELIEVES THE COMPLAINT IS MERITLESS AND ILLUSTRATES A FUNDAMENTAL MISUNDERSTANDING BY THE DOJ OF DRUG PRICE REPORTING STANDARDS
Reuters · 4d ago
REGENERON - THE FILING OF THIS LAWSUIT WILL NOT CHANGE OUR PRACTICES WITH RESPECT TO REIMBURSEMENT OF CREDIT CARD FEES INCURRED BY OUR DISTRIBUTORS.
Reuters · 4d ago
More
Webull provides a variety of real-time REGN stock news. You can receive the latest news about Regeneron Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others. The Company’s solid tumor and other oncology and autoimmune cell therapy programs include the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets.